As per available reports about 66 relevant journals, 15 Conferences, 1395 workshops are presently dedicated exclusively to breathing disorder and about 3040 articles are being published on Infectious Diseases.

An Emerging Infectious Disease (EID) is an infectious disease whose incidence has increased in the past 35 years and could increase in the near future. Emerging infections account for at least 12% of all human pathogens. EIDs are caused by newly identified species or strains (e.g. SARS, AIDS) that may have evolved from a known infection (e.g. influenza) or spread to a new population (e.g. West Nile virus) or area undergoing ecologic transformation (e.g. Lyme disease) or be re emerging infections like drug resistant tuberculosis. Of growing concern are adverse synergistic interactions between emerging diseases and other infectious and non infectious conditions leading to the development of novel syndemics.

OMICS International Organizes 1000+ Global Events Every Year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open access journals which contains over 100000 eminent personalities, reputed scientists as editorial board and organizing committee members. The conference series website will provide you list and details about the conference organize worldwide.

Scope and Importance

The following factors contributing to Emerging Infectious Diseases

1. Changing human susceptibility for e.g. mass immunecompromisation with HIV/ AIDS

2. Microbial adaption for e.g. genetic drift and genetic shift in Influenza A

3. Climate and weather for e.g. diseases with zoonotic vectors such as West Nile Disease

(transmitted by mosquitoes) are moving further from the tropics as the climate warms

4. Change in human demographics and trade for e.g. rapid travel enabled SARS to rapidly propagate around the globe

5. Economic development for e.g. use of antibiotics to increase meat yield of farmed cows leads to antibiotic resistance

6. Breakdown of public health for e.g. the current situation in Zimbabwe

7. Poverty and social inequality for e.g. tuberculosis is primarily a problem in low-income areas

8. War and famine

9. Bioterrorism for e.g. 2001 Anthrax attacks

10. Dam and irrigation system construction for e.g. malaria and other mosquito borne diseases

The following are the additional Emerging Infectious Diseases/ Pathogens

• Acanthamebiasis

• Anaplasmosis (new in FY14)

• Aspergillus (new in FY14)

• Australian bat lyssavirus

• Babesia, atypical

• Bartonella henselae

• BK virus (new in FY14)

• Borrelia miyamotoi (new in FY14)

• Clostridium difficile

• Cryptococcus gattii (new in FY14)

• Ehrlichiosis

• Enterococcus faecium and faecalis (new in FY14)

• Enterovirus 71

• Hepatitis C (new in FY14)

• Hepatitis E (new in FY14)

• Human herpesvirus 8

• Human herpesvirus 6

• JC virus (new in FY14)

• Leptospirosis (new in FY14)

• Lyme borreliosis

• Mucormycosis (new in FY14)

• Mumps virus

• Rubeola (measles) (new in FY14)

• Streptococcus, Group A

• Staphylococcus aureus

Market Analysis

Infectious diseases therapeutic market

The infectious diseases therapeutic market in US is estimated to grow at a rate of 3.37% between 2014- 2019. As per the records, 25% of deaths are mainly due to infectious diseases globally. Current market trend shows that North America has the more global market for infectious diseases therapeutics due to increasing incidence of infectious diseases and due to rise in aging population. Followed by North America highest global market is expected in Asia then followed by the Europe in the global infectious diseases therapeutics market. In Asia-Pacific region, China and India are expected to be the fastest growing infectious diseases therapeutics markets. The main reasons behind the highest global market of infectious diseases therapeutics market in the above countries is mainly due to large number of patients and due to increase in government funding. Some of the major companies playing a key role in the global infectious diseases therapeutics market are Merck & Co., Pfizer, Johnson & Johnson, F. Hoffmann-La Roche, GlaxoSmithKline Pharmaceutical, Inc., Auritec Pharmaceuticals, Novartis, Achillion Pharmaceuticals, Isis Pharmaceuticals and Gilead Sciences.

Infectious diseases diagnostics market

Market for infectious disease molecular diagnostics tests includes hospitals, blood banks, reference laboratories. North America has the highest global market for molecular diagnostics tests followed by Europe due to the market availability of the tests and high occurrence rate of various infectious diseases such as HPV, hepatitis and bacterial infections. Asia Pacific, Latin America and Middle East are expected to be the potential markets in the coming years. Major companies which play a key role in infectious disease molecular diagnostics tests market are Abbott Laboratories, Affymetrix, Inc., Becton, Dickinson and Company, bioMérieux, Cepheid, Inc., Hologic, Inc., Life Technologies, Myriad Genetics, Inc., Qiagen N.V. and others.